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Cardiovascular diseases (CVDs) are a common co-morbidity among patients with chronic 
obstructive pulmonary disease (COPD) with prevalence estimates ranging from 30 to 60% in 
“real-world” studies (1). CVDs have adverse consequences for COPD patients by reducing their 
quality of life, increasing their risk of exacerbations, prolonging exacerbations and 
hospitalizations and contributing to their premature mortality (2). Indeed, most large studies 
suggest that 30 to 50% of deaths in patients with COPD are primarily driven by the patients’ 
underlying CVDs, though establishing clear causality of deaths is extremely challenging (3, 4). 
Furthermore, it is recognized that people living with COPD do not always benefit from effective 
primary and secondary prevention including the appropriate use of beta-blocker drugs (1). 
While the importance of CVDs in COPD has been well established, COPD as a risk factor for 
CVDs is less well known. Not surprisingly, most major CVD consensus guidelines do not list 
COPD as an important risk factor for CVDs (5). Whilst some cardiovascular (CV) risk prediction 
such as QRISK (https://qrisk.org/) include selected chronic inflammatory conditions such as 
rheumatoid arthritis, COPD is not included (6). Although previous studies have shown that 
reduced lung function is associated with future risk of CV events including myocardial infarction 
(MI), heart failure, and sudden deaths even among life-time non-smokers, how (and why) this 
occurred is largely unknown (7). Kunisaki and colleagues performed a secondary analysis of the 
Study to Understand Mortality and MorbidITy (SUMMIT) trial to fill in some critical gaps in 
knowledge regarding the relationship of COPD with CVDs (8). They showed that CVD events 
occurred mostly during periods of acute exacerbations (AECOPD) with the highest risk 
occurring within the first 30 days of AECOPD (relative risk, RR, 3.8) and with the risk returning 
to baseline levels at 1 year post-AECOPD. The risk was particularly notable when the 
presentation of the AECOPD event – a composite of the severity of the underlying COPD and of 
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the trigger - was severe enough to warrant a hospitalization. Remarkably, with these serious 
AECOPDs, the RR of a CV event was 10-fold higher in the first 30 days post-hospitalization.   
Although such associations have been previously reported (9), there were strengths to the 
SUMMIT trial that addressed many of the concerns of previous epidemiological and clinical 
studies that have been published on this topic (1). First, SUMMIT’s sample size was 
impressively large (n=16,485) and international and the investigators enrolled patients with co-
existing CVD or who had a high risk of CVD, which provided sufficient power to dynamically 
estimate the risk of CV events following AECOPDs. Second, there was careful follow-up of 
patients with a face-to-face review, which occurred every 3 months over a median follow-up of 
1.5 years, ensuring complete and accurate ascertainment of CV events and AECOPD. Third, the 
investigators used a well-established and accepted definition of AECOPD and most importantly 
objectively adjudicated all CV events using standardized protocols, which minimized the risk of 
misclassification that could have biased the results. Fourth, the investigators enrolled patients 
with COPD using well-accepted spirometric and clinical criteria dissimilar to many previous 
large studies that relied on reduced lung function alone (without exposure or symptoms) or on 
physician or self-reported diagnosis of COPD, which could have led to diagnostic 
misclassification.  
SUMMIT also has had some limitations. The most notable was that SUMMIT was not powered 
on CVD events; it was a clinical trial, powered on total mortality. As such, some important 
information regarding AECOPD was not captured. Although SUMMIT and other studies 
considered AECOPD as a distinct entity, in reality, the causes of AECOPDs are heterogeneous. 
Viral respiratory tract infections are thought to be the most common triggers for AECOPD; 
however, in a large number of cases, the etiology of AECOPD is non-infectious or unknown. 
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Indeed, it is possible that some of the AECOPD events in SUMMIT could have been due to 
congestive heart failure or myocardial ischemia. To this end, data on cardiac troponins, or brain 
natriuretic peptide along with information on sputum cultures and thoracic computed 
tomography scans (to rule out pulmonary embolism or pneumonia) would have been invaluable 
in determining the etiology of symptom deteriorations labelled as AECOPDs in SUMMIT. In 
addition, SUMMIT only recruited people with COPD between FEV1 50 and 70% predicted 
limiting generalizability, especially in those admitted to hospital. Finally, these data do not 
inform on the underlying mechanism of interaction between AECOPD and CVD events.  Only 
by understanding this – systemic inflammation, pro-coagulant status or hypoxia to name but 
three possibilities – can we hope to design rational trials to mitigate this risk. 
Notwithstanding these limitations, Kunisaki and colleagues’ analysis provides compelling 
evidence that COPD is a significant risk factor for CV events, especially during AECOPDs. We 
postulate that the risk of CV in COPD is, at least in part, due to persistent airway inflammation, 
which increases sharply during AECOPDs that are driven by viral or bacterial infections. Using a 
large health database in Ontario, Canada, Kwong et al showed that acute viral respiratory tract 
infections especially from influenza was associated with a 6 to 10-fold increase in the risk of MI 
during the first 7 days of infection compared to baseline (non-infectious) periods (10). These 
data are also consistent with those of Smeeth et al which showed increased risk of MI and stroke 
following respiratory tract infections (either viral or bacterial) (11). These epidemiological data 
are supported by experimental results, which showed that acute airway exposure of 
lipopolysaccharide (LPS), a bioactive component of cell wall of gram negative bacteria, which 
have also been implicated in AECOPD, in mice leads to acute atherosclerotic plaque rupture (12). 
In this study, inhibition of neutrophils or its component, myeloperoxidase, prevented plaque 
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rupture related to acute intratracheal LPS exposure, suggesting a crucial role of neutrophil 
activation in this process.  
What have we learned from this SUMMIT analysis and, more importantly, how do we improve 
health outcomes of our patients with COPD using this information? The SUMMIT data raise the 
possibility that by preventing or reducing the severity of AECOPDs, we may be able to reduce 
CV events, though it was disappointing that neither inhaled corticosteroids (ICS) nor long-acting 
beta 2 agonists (LABA) by themselves or in combination significantly reduced CV events or 
mortality in this trial. Nevertheless, reducing AECOPD should be a primary goal for patients 
with frequent exacerbations. To this end, annual influenza vaccination, which reduces both 
AECOPD and CV events, should be rigorously recommended for all patients with COPD (13). 
SUMMIT also raises the possibility of using cardioprotective medications such as aspirin, statins 
or beta-blockers for patients with COPD and co-existing CVDs or at high risk of CVDs. Several 
studies are currently underway to address this critical question. Until these results are available, 
we believe that all patients with COPD should be assessed for cardiovascular risk (if they do not 
already have a coexisting CVD) and be treated with appropriate cardio-protective medications 
when the risk is deemed sufficiently high. Furthermore, given the high prevalence of coexisting 
CVD in the COPD patient population in the real-world, these patients should not be excluded in 
any therapeutic trials to ensure that the results are applicable to these patients.   
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